Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Executive Vice President | January 31, 2017 | February 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date January 31, 2017 · Filed February 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-01-31 transaction · row 1
1 source rowRow 1 · 2017-01-31 · Sale · Disposed 11,704 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 to $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 to $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2017 Filed Feb 2, 2017 21:13 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | SaleCommon Stock | 11,704 | $12.59 | $147,353.36 |
DisclosureSEC source: 0001437749-17-001544 · rdgdoc.xml · nonDerivative · entry 1 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 to $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 17:31 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001437749-17-000906 · rdgdoc.xml · derivative · entry 3 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 Underlying: Common Stock · 2,500 shares Expires 2017-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 17:31 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 1,135 | $12.40 | $14,074.00 |
DisclosureSEC source: 0001437749-17-000906 · rdgdoc.xml · nonDerivative · entry 2 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,704 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 17:31 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 2,500 | $5.63 | $14,075.00 |
DisclosureSEC source: 0001437749-17-000906 · rdgdoc.xml · nonDerivative · entry 1 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 23:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 6,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-16-040131 · rdgdoc.xml · derivative · entry 2 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 Underlying: Common Stock · 6,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 23:36 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 6,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-16-040131 · rdgdoc.xml · derivative · entry 1 HIEBERT LARRY D · CIK 0001282719 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 Underlying: Common Stock · 6,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F3 · derivative.expiration_date: Restricted Stock Units will vest on the 2nd anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.